MHRA approves Kostaive sa-mRNA COVID booster for adults

Here is the update we will be teaching from this week. On 2 January 2026, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved zapomeran (brand name Kostaive), a COVID-19 vaccine for people aged 18 and over. This adds another booster option for adults.

What this means for you: the product is given as a single 0.5 mL booster injected into the muscle of the upper arm. Approval confirms it meets UK standards; the NHS will decide who is offered it and when, so look out for local invitations if you are eligible.

Quick science to share in class: this is a self-amplifying mRNA (sa-mRNA) vaccine. mRNA is a temporary instruction. For a short time after the jab, some cells make a small, harmless copy of the coronavirus spike protein so your immune system can practise. Then the mRNA is broken down by the body.

Common and short-term effects reported with this vaccine include a sore or tender arm where the injection went in, tiredness, chills, fever, muscle and joint aches, headache and dizziness. The MHRA notes these very common effects may affect more than 1 in 10 people and usually settle within a few days; fuller details will be in the Patient Information Leaflet and the Summary of Product Characteristics within seven days of approval.

If you think you are experiencing a side effect, speak to a doctor, pharmacist or nurse and report it to the MHRA Yellow Card scheme. You can report online at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app. These reports help the regulator monitor safety as wider use begins.

For policy and regulation students, the approval used the MHRA’s International Recognition Procedure, with the European Medicines Agency acting as the Reference Regulator (EMA code EMEA/H/C/006207/0000). In plain terms, the MHRA considered trusted EMA evidence alongside its own checks before allowing UK use.

What to watch next: the MHRA says the PIL and SmPC will be published within seven days of 2 January 2026. Use them to practise reading official medicine information and translating technical points for parents, colleagues or classmates.

Classroom activity suggestion: invite students to explain, in 100 words, how sa-mRNA vaccines teach immunity, then draft a sample Yellow Card report using a fictional scenario, noting symptoms and timing. This builds practical health literacy and clear communication.